VX15/2503 ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	1
13	多発性硬化症／視神経脊髄炎	1

8. ハンチントン病

---

臨床試験数 : 229 /  薬物数 : 193 - (DrugBank : 60) / 標的遺伝子数 : 84 - 標的パスウェイ数 : 158

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02481674 (ClinicalTrials.gov)	July 2015	19/6/2015	A Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503)	A Phase 2, Multi-center, Randomized, Double-blind, Placebo Controlled Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of VX15/2503	Huntington's Disease	Drug: VX15/2503;Drug: Placebo	Vaccinex Inc.	Huntington Study Group	Completed	21 Years	N/A	All	301	Phase 2	United States;Canada

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01764737 (ClinicalTrials.gov)	December 2012	3/1/2013	Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS	A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study Of The Safety, Tolerability, And Pharmacokinetics Of Intravenous VX15/2503 In Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: VX15/2503;Drug: Placebo	Vaccinex Inc.	PRA Health Sciences	Completed	18 Years	60 Years	Both	50	Phase 1	United States